GlaxoSmithKline has announced that its current chief operating officer Luke Miels would take over as chief executive.
The company, one of the world’s biggest drugmakers, launched the first ever malaria vaccine in 2021, and is now conducting human trials on a second malaria vaccine which will include an additional antigen to improve immune response.
It said Miels – previously responsible for medicines and vaccines – would take over from current chief Dame Emma Walmsley at the start of next year.
“The inspiring people in our labs, factories, and markets worldwide are delivering innovation that matters to get ahead of disease,” said Walmsley in a statement. “I know Luke will lead them brilliantly to even greater impact for patients.”
The company added that Miels would get a base salary of GBP 1.375 million per year, less than the amount earned by his predecessor, with a bonus of 150 to 300 per cent depending on performance.
“GSK is a very special company, with outstanding prospects and enormous capacity to impact people’s health and to change lives,” Miels said in a statement.
